Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

15.56 -0.33 (-2.08%)
Streaming Delayed Price Updated: 1:45 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
3 Reasons BLCO is Risky and 1 Stock to Buy Instead
Even during a down period for the markets, Bausch + Lomb has gone against the grain, climbing to $16.01. Its shares have yielded a 10.4% return over the last... 
Via StockStory
Topics Bankruptcy
News headline image
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story ↗
Bausch + Lomb, a global leader in eye health products and surgical devices, reported a recent insider buy amid ongoing sector activity. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Billboard Giant Posts $1.6 Billion Revenue as $20.5 Million Bet Makes It a Top Portfolio Holding ↗
This outdoor advertising firm operates a vast network of displays across the Americas and Europe, serving a diverse global client base. 
Via The Motley Fool
Topics Regulatory Compliance
Bausch + Lomb Corp (NYSE:BLCO) Reports Mixed Q4 2025 Results: Revenue Beat, EPS Miss ↗
Via Chartmill
News headline image
Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position ↗
Bausch + Lomb provides eye health products and surgical devices globally, serving both healthcare professionals and consumers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know
Via StockStory
Topics Earnings Economy
News headline image
2 Profitable Stocks Worth Investigating and 1 We Ignore
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive
As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent... 
Via Finterra
Topics Economy Initial Public Offering Retirement
News headline image
5 Revealing Analyst Questions From Bausch + Lomb’s Q4 Earnings Call
Bausch + Lomb’s fourth quarter showed strong revenue growth but fell short on non-GAAP profit expectations, prompting a modestly negative market reaction. Management attributed the performance to... 
Via StockStory
Topics Earnings
News headline image
3 Small-Cap Stocks We Steer Clear Of
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
News headline image
BLCO Q4 2025 Deep Dive: Dry Eye and Product Innovation Propel Growth, Margin Expansion in Focus
Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q4 CY2025, with sales up 9.8% year on year to $1.41 billion. The company’s full-year revenue guidance of $5.43... 
Via StockStory
News headline image
Bausch + Lomb’s (NYSE:BLCO) Q4 CY2025: Beats On Revenue
Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q4 CY2025, with sales up 9.8% year on year to $1.41 billion. The company’s full-year revenue guidance of $5.43... 
Via StockStory
News headline image
Bausch + Lomb (BLCO) Q4 Earnings: What To Expect
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting results this Wednesday before market hours. Here’s what to look for. 
Via StockStory
Topics World Trade
News headline image
3 Reasons to Sell BLCO and 1 Stock to Buy Instead
Bausch + Lomb’s 24.2% return over the past six months has outpaced the S&P 500 by 15.6%, and its stock price has climbed to $16.93 per share. This was partly thanks to its solid quarterly results, and... 
Via StockStory
Topics Bankruptcy Stocks
News headline image
1 Healthcare Stock to Research Further and 2 Facing Headwinds
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare... 
Via StockStory
Topics Stocks
News headline image
3 Stocks Under $50 That Fall Short
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
News headline image
3 Cash-Burning Stocks We’re Skeptical Of
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even... 
Via StockStory
Topics Bankruptcy
News headline image
1 Profitable Stock to Keep an Eye On and 2 We Question
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year ↗
Strong operating results did not stop one fund from walking away entirely, raising questions about how much patience volatile healthcare names really command. 
Via The Motley Fool
News headline image
Why Bausch + Lomb (BLCO) Stock Is Trading Up Today
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 2.2% in the morning session after Citigroup upgraded its rating on the company's shares to Buy from Neutral and raised its price target. The... 
Via StockStory
Topics Artificial Intelligence Initial Public Offering
News headline image
3 Healthcare Stocks We Think Twice About
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the... 
Via StockStory
Topics Stocks
News headline image
BLCO Stock Still 16% Below IPO — Is Silver Point’s $38.7 Million Bet a Turning Point? ↗
One fund just made a bold move on an eye-care giant—here’s why it may signal a deeper shift in the company’s long-term trajectory. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Why Bausch + Lomb (BLCO) Stock Is Up Today
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 4.2% in the morning session after Morgan Stanley upgraded its rating on the stock to "Overweight" from "Equal Weight.". The investment bank... 
Via StockStory
Topics Economy Initial Public Offering
News headline image
3 Small-Cap Stocks with Warning Signs
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
News headline image
3 Cash-Burning Stocks We Approach with Caution
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable. 
Via StockStory
News headline image
Option Care Health, DaVita, Revvity, West Pharmaceutical Services, and Bausch + Lomb Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated... 
Via StockStory
Topics Economy
News headline image
Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid... 
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
Medical Devices & Supplies - Specialty Stocks Q3 In Review: Bausch + Lomb (NYSE:BLCO) Vs Peers
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - specialty stocks fared in Q3,... 
Via StockStory
News headline image
5 Revealing Analyst Questions From Bausch + Lomb’s Q3 Earnings Call
Bausch + Lomb’s third quarter saw a positive market response, as the company posted growth across all major segments and met Wall Street’s revenue expectations. Management highlighted that strong... 
Via StockStory
Topics Earnings
News headline image
BLCO Q3 Deep Dive: Pharmaceuticals and Pipeline Drive Growth, Margin Initiatives Take Shape
Eyecare company Bausch + Lomb (NYSE:BLCO) met Wall Streets revenue expectations in Q3 CY2025, with sales up 7.1% year on year to $1.28 billion. The company’s outlook for the full year was close to... 
Via StockStory
Topics World Trade
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.